Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  EbM & Individualisierte Medizin; 12. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; 20110324-20110326; Berlin; DOC11ebm24 /20110323/
    Publication Date: 2011-03-23
    Keywords: ddc: 610
    Language: German
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  Kongress Medizin und Gesellschaft 2007; 20070917-20070921; Augsburg; DOC07gmds386 /20070906/
    Publication Date: 2007-09-07
    Keywords: postmenopausal breast cancer risk ; menopausal hormone therapy use ; ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    facet.materialart.
    Unknown
    German Medical Science GMS Publishing House; Düsseldorf
    In:  Kongress Medizin und Gesellschaft 2007; 20070917-20070921; Augsburg; DOC07gmds001 /20070906/
    Publication Date: 2007-09-07
    Keywords: ddc: 610
    Language: English
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    facet.materialart.
    Unknown
    German Medical Science; Düsseldorf, Köln
    In:  50. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie (gmds), 12. Jahrestagung der Deutschen Arbeitsgemeinschaft für Epidemiologie; 20050912-20050915; Freiburg im Breisgau; DOC05gmds196 /20050908/
    Publication Date: 2005-09-09
    Keywords: ddc: 610
    Language: German
    Type: conferenceObject
    Signatur Availability
    BibTip Others were also interested in ...
  • 5
    Keywords: CANCER ; Germany ; TOOL ; DISEASE ; DISEASES ; EPIDEMIOLOGY ; TIME ; BREAST ; breast cancer ; BREAST-CANCER ; HUMANS ; AGE ; WOMEN ; case-control studies ; body mass index ; QUESTIONNAIRE ; questionnaires ; INTERVIEW ; breast neoplasms ; exercise ; physical activity ; ADULT ; PHYSICAL-ACTIVITY ; LEVEL ; technique ; female ; UNIT ; cancer research ; Aged ; Middle Aged ; AGREEMENT ; retrospective ; Retrospective Studies ; Interviews ; Physical Fitness ; Random Allocation ; telephone
    Abstract: Physical activity (PA) is discussed as a preventive factor for many chronic diseases. Thus, in epidemiological studies it often is an important covariate. Due to frequently long latency periods, long-term PA in the past is of greater interest than current PA. However, there is a lack of retrospective questionnaires that are validated for long-term PA, including occupational, household, and leisure activities. We therefore evaluated a short questionnaire for the comprehensive assessment of usual PA in distant age periods, administered with cognitive interviewing techniques. From an ongoing study on postmenopausal breast cancer 110 cases and 101 controls, age 50-74 years, were randomly selected. Our questionnaire was administered in a telephone interview more than two months after the main study interview, which included a detailed questionnaire on PA performed in the age periods 30-49 years and 50+ years. Total PA scores were derived from both interviews as MET-hours per week. Degree of agreement was assessed using Bland-Altman analyses. Further, potential sources of systematic and random error were investigated. The mean difference between both questionnaires was 3 MET hours/week, and 53.6% of absolute differences were below 35 MET hours/week, i.e. showing good agreement. Further 28.9% of differences could be considered acceptable agreement. Measurement errors seem to be non-differential with respect to cancer status. The median interviewing time was 10 min. Overall, this short questionnaire appears to be a useful and valid tool to distinguish between high and low levels of women's physical activity in the distant past
    Type of Publication: Journal article published
    PubMed ID: 17004027
    Signatur Availability
    BibTip Others were also interested in ...
  • 6
    Keywords: CANCER ; Germany ; THERAPY ; INFORMATION ; DISEASE ; RISK ; validation ; BREAST ; breast cancer ; BREAST-CANCER ; NO ; hormone ; HEALTH ; DESIGN ; NUMBER ; AGE ; HORMONE REPLACEMENT THERAPY ; cancer risk ; REGION ; REGIONS ; RELIABILITY ; case-control studies ; BREAST-CANCER RISK ; POSTMENOPAUSAL WOMEN ; breast neoplasms ; case control study ; case-control study ; RE ; DETERMINANTS ; THERAPIES ; RECALL ; ESTROGEN ; case control studies ; INTERVAL ; RANDOMIZED CONTROLLED-TRIAL ; REPLACEMENT THERAPY ; correlation ; population-based ; CANCER-RISK ; AGREEMENT ; case control ; postmenopausal ; comparison ; validation studies ; prescription ; ESTROGEN REPLACEMENT THERAPY ; postmenopause ; RECORDS
    Abstract: Objective: In a population-based case-control study examining the effects of postmenopausal hormone therapy (HT) on breast cancer risk, the authors conducted a validation study comparing prescription data from gynecologists with self-reports. Study Design and Setting: The study was conducted in the Rhein-Neckar and Hamburg regions of Germany from 2002 to 2005. A total of 224 cases and 225 controls, stratified by region, age, and hormone use were randomly selected for the validation study. Results: For ever/never use 88.2% agreement was seen, and agreement for ever/never use by type of HT was 80.6%, 80.3%, and 90.5% for mono-estrogen, cyclical combined, and continuous combined therapy, respectively. The intraclass correlation coefficient (ICC) for duration of use was high, 0.82 (95% confidence interval [CI]: 0.77, 0.85), as were the ICCs for age at first and last use, 0.88 (95% CI: 0.85, 0.91) and 0.98 (95% CI: 0.97, 0.98). Despite the exceptionally high number of different HT prescriptions available in Germany, comparison of exact brand name resulted in perfect agreement for 50.2% of participants, partial agreement for 29.3%, and no agreement for 20.7%. In general, agreement was not differential by disease status. Conclusion: Overall, the self-reported HT of the study participants corresponded well with physicians' reports. (C) 2007 Elsevier Inc. All rights reserved
    Type of Publication: Journal article published
    PubMed ID: 17998083
    Signatur Availability
    BibTip Others were also interested in ...
  • 7
    Keywords: CANCER ; Germany ; POPULATION ; RISK ; GENES ; PROTEIN ; PROTEINS ; TRANSDUCTION ; PATIENT ; ACTIVATION ; MECHANISM ; IMPACT ; CARCINOGENESIS ; signal transduction ; ASSOCIATION ; polymorphism ; POLYMORPHISMS ; SUSCEPTIBILITY ; BREAST ; breast cancer ; BREAST-CANCER ; MUTATION ; SIGNAL-TRANSDUCTION ; cancer risk ; ONCOLOGY ; RE ; BRCA2 ; INCREASE ; analysis ; TESTS ; USA ; BINDING DOMAIN ; CANCER-RISK ; EPITHELIAL OVARIAN-CANCER ; KINASE-ANCHORING PROTEINS
    Abstract: Data from several studies have suggested that polymorphisms in A-kinase anchoring proteins (AKAPs), which are key components of signal transduction, contribute to carcinogenesis. To evaluate the impact of AKAP variants on breast cancer risk, we genotyped six nonsynonymous sing le-nucleotide polymorphisms that were predicted to be deleterious and found two (M4631, 1389G〉T and N2792S, 8375A〉G) to be associated with an allele dose-dependent increase in risk of familial breast cancer in a German population. We extended the analysis of AKAP9 M4631, which is in strong linkage disequilibrium with AKAP9 N2792S, to 9523 breast cancer patients and 13770 healthy control subjects from seven independent European and Australian breast cancer studies. All statistical tests were two-sided. The collaborative analysis confirmed the association of M4631 with increased breast cancer risk. Among all breast cancer patients, the combined adjusted odds ratio (OR) of breast cancer for individuals homozygous for the rare allele TT (frequency = 0.19) compared with GG homozygotes was 1.17 (95% confidence interval [CL] = 1.08 to 1.27, P =.0003), and the OR for TT homozygotes plus GT heterozygotes compared with GG homozygotes was 1.10 (95% Cl = 1.04 to 1.17, P=.001). Among the combined subset of 2795 familial breast cancer patients, the respective ORs were 1.27 (95% Cl = 1.12 to 1.45, P =.0003) and 1.16 (95% Cl = 1.06 to 1.27, P =.001)
    Type of Publication: Journal article published
    PubMed ID: 18334708
    Signatur Availability
    BibTip Others were also interested in ...
  • 8
  • 9
    Keywords: CANCER ; EXPRESSION ; BLOOD ; Germany ; THERAPY ; INFORMATION ; RISK ; TIME ; PATIENT ; RISK-FACTORS ; CARCINOGENESIS ; ASSOCIATION ; BREAST ; breast cancer ; BREAST-CANCER ; WOMEN ; risk factors ; cancer risk ; DIETARY ; case-control studies ; CALCIUM ; DIETARY-INTAKE ; CELL-GROWTH ; SERUM ; ONCOLOGY ; case-control study ; REGRESSION ; RE ; THERAPIES ; ESTROGEN ; analysis ; RISK-FACTOR ; CANCER-RISK ; ENGLAND ; VITAMIN-D-RECEPTOR ; VITAMIN-D ; postmenopausal ; PERSONAL INTERVIEW ; D METABOLITES ; 1,25-DIHYDROXYVITAMIN-D RECEPTORS ; D DEFICIENCY ; HYPOVITAMINOSIS-D
    Abstract: Various studies suggest that vitamin D may reduce breast cancer risk. Most studies assessed the effects of dietary intake only, although endogenous production is an important source of vitamin D. Therefore, the measurement of serum 25-hydroxyvitamin D [25(OH)D] better indicates overall vitamin D status. To assess the association of 25(OH)D serum concentrations with post-menopausal breast cancer risk, we used a population-based case-control study in Germany, which recruited incident breast cancer patients aged 50-74 between 2002 and 2005. Information on sociodemographic and breast cancer risk factors was collected by personal interview. For this analysis, we included 1394 cases and 1365 controls, matched on year of birth and time of blood collection. Conditional logistic regression was used to calculate odds ratios (ORs) for breast cancer adjusted for potential confounders. Serum 25(OH)D concentration was significantly inversely associated with post-menopausal breast cancer risk. Compared with the lowest category (〈 30 nM), OR [95% confidence intervals (CI)] for the higher categories of 25(OH)D (30-45, 45-60, 60-75 and 〉= 75 nM) were 0.57 (0.45-0.73), 0.49 (0.38-0.64), 0.43 (0.32-0.57) and 0.31 (0.24-0.42), respectively (P-trend 〈 0.0001). Analysis using fractional polynomials indicated a non-linear association. The association was stronger in women never using menopausal hormone therapy (HT) compared with past and current users (P-interaction 〈 0.0001). Our findings strongly suggest a protective effect for post-menopausal breast cancer through a better vitamin D supply as characterized by serum 25(OH)D measurement, with a stronger inverse association in women with low serum 25(OH)D concentrations (〈 50 nM)
    Type of Publication: Journal article published
    PubMed ID: 17974532
    Signatur Availability
    BibTip Others were also interested in ...
  • 10
    Keywords: RECEPTOR ; APOPTOSIS ; CANCER ; tumor ; carcinoma ; Germany ; PATHWAY ; PATHWAYS ; THERAPY ; SUPPORT ; LONG-TERM ; RISK ; RISKS ; TUMORS ; BIOMARKERS ; ASSOCIATION ; DISORDER ; BREAST ; breast cancer ; BREAST-CANCER ; hormone ; IN-SITU ; PATTERNS ; HEALTH ; WOMEN ; cancer risk ; CARCINOMAS ; case-control studies ; ER ; ESTROGEN-RECEPTOR ; CYTOTOXICITY ; POSTMENOPAUSAL WOMEN ; DISORDERS ; case control study ; case-control study ; REGRESSION ; THERAPIES ; ESTROGEN ; biomarker ; estrogen receptor ; USA ; phytoestrogens ; SOY INTAKE ; cancer research ; CANCER-RISK ; hormone therapy ; CONFIDENCE ; EXTRACTS ; PROGESTERONE-RECEPTOR ; RECEPTOR STATUS ; BLACK COHOSH ; ESTROGEN-RECEPTOR-BETA ; GROWTH-INHIBITORY ACTIVITY ; HORMONE-RELATED SUPPLEMENTS ; MDA-MB-453 CELLS ; MENOPAUSAL SYMPTOMS
    Abstract: Background:The use of herbal preparations (HEP) to alleviate climacteric disorders is expected to increase as women seek alternatives to menopausal hormone therapy to avoid the associated breast cancer risk. Data are sparse on the long-term effects of HEP containing phytoestrogens and black cohosh on breast cancer risk. Methods: Within a German case-control study, associations between patterns of HEP use and incident breast cancer were investigated in 10,121 postmenopausal women (3,464 cases, 6,657 controls). Information on HEP use was collected in face-to-face interviews supported by a list of brand names. Multivariate logistic and polytomous regression analyses were done. Findings: Ever use of HEP (9.9%) was inversely associated with invasive breast cancer [odds ratio (OR), 0.74; 95% confidence interval (CI), 0.63-0.87] in a dose-dependent manner (OR, 0.96 per year of use; P = 0.03). Classes of HEP did not differ significantly (P-heterogeneity = 0.81). Risks for invasive ductal (OR, 0.72; 95% CI, 0.60-0.87) and combined lobular/mixed/tubular tumors (OR, 0.76; 95% Cl, 0.58-1.01) were similarly reduced by any HEP use but not for in situ carcinomas (1.34; 95% CI, 0.86-2.09). There were no substantial differences in associations of HEP use by estrogen receptor status (ER+ OR, 0.74; 95% Cl, 0.62-0.89; ER- OR, 0.68, 95% CI, 0.50-0.93) and progesterone receptor status of the tumor. Interpretation: Our findings support the hypothesis that HEP use protects from invasive breast cancer in postmenopausal women. Among conceivable modes of action, those independent of estrogen receptor-mediated pathways seem to be involved (i.e., cytotoxicity apoptosis). (Cancer Epidemiol Biomarkers Prev 2009;18(8):2207-13)
    Type of Publication: Journal article published
    PubMed ID: 19661079
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...